We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SEC Accuses Trio of Violating Law to Profit from GE-Clarient Deal

SEC Accuses Trio of Violating Law to Profit from GE-Clarient Deal

September 11, 2015

Three men have agreed to settle U.S. Securities and Exchange Commission charges that they engaged in insider trading ahead of GE Healthcare’s 2010 purchase of Clarient, a cancer diagnostics company.

According to documents filed in the U.S. District Court for the Northern District of California, businessman John McEnery III allegedly tipped off his son, John McEnery IV, and a close friend, Michael Rawitser, about the acquisition.

The elder McEnery had been informed by a senior director at Clarient — a woman whom he had dated on and off since the 1990s — about the buyout. “Given their history, pattern and practice of sharing confidences, the Clarient Insider expected McEnery III to keep the information regarding the Clarient acquisition confidential,” court documents state. Instead he “misappropriate[d] the information about the Clarient acquisition to unlawfully enrich himself and others.”

The SEC accuses McEnery of “knowingly and/or recklessly” trading on the information and encouraging his son and friend to do the same. The three began purchasing shares of Clarient and sold them for a profit after the merger was announced, reeling in more than $50,000.

The three have agreed to pay a combined sum of approximately $170,000 to settle the charges, without admitting or denying the accusations. The settlement is subject to the court’s approval.

“Individuals who obtain confidential information through a relationship of trust with a corporate insider are prohibited from using that information to trade securities,” says Joseph G. Sansone, acting co-chief of the SEC’s Market Abuse Unit.  “These traders violated such a trust by using highly sensitive information to reap illicit trading profits.” — Elizabeth Hollis

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • FDA clears text

    Vetex Medical’s Thrombectomy Catheter Cleared by FDA

  • 100Bills_flatmoney.gif

    Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion

  • abbott-logo.gif

    Abbott Gets FDA EUA for COVID-19 IgG Antibody Test

  • 100Bills_flatmoney.gif

    In $1.55 Billion Deal, Perrigo Sells Off Generic Drug Business

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing